FDA panel approves outcomes claim for Vytorin

The FDA advisory panel reviewing a new indication for Merck's ($MRK) cholesterol fighter Vytorin gave the drug a nod for preventing cardiovascular problems in patients with kidney disease, but voted against the indication for kidney patients on dialysis. Report

Suggested Articles

Creating a relevant online health user experience has its payoffs — for both the user and the brand. Here’s why.

Sanofi's new strategy delivered for the drugmaker in the third quarter as Dupixent posted blockbuster sales and flu vaccines set a revenue record.

Catalent has acquired Bone Therapeutics' cell and gene therapy site in Gosselies, Belgium, to add to its growing "center of excellence" there.